HanmiCap: Advancing mRNA Therapeutics with Innovative Cap Analogs
- Introducing novel 5′ cap analogs featuring m7GpppA modifications that enhance mRNA translation efficiency and reduce dsRNA levels, delivering superior outcomes in mRNA therapeutics
- Its highly efficient manufacturing process enables large-scale, high-purity production at significantly lower cost, providing a clear cost-down advantage for both mRNA research and commercial applications
- Hanmi Fine Chemical leverages its CDMO expertise and continuous innovation to supply GMP-ready HanmiCap samples with no running royalties, supporting economical and scalable mRNA development from preclinical to clinical stages